Isomorphic Labs Seeks Over $2 Billion in New Funding Round

Thrive Capital and Alphabet are expected to back a major new financing round for Isomorphic Labs as interest in AI-powered drug discovery continues to grow.

Isomorphic Labs, the AI drug discovery company spun out of Alphabet’s Google DeepMind, is in advanced discussions to raise more than $2 billion in a new funding round, according to a report by Bloomberg.

Thrive Capital, the venture firm that led Isomorphic Labs’ first external funding round in 2025, is expected to lead the new financing, with Alphabet also participating, according to sources familiar with the matter. The funding round is still under discussion and has not yet been finalized.

The London-based company plans to use the new capital to strengthen its AI-powered drug design platform and support global expansion, though the valuation of the round has not been disclosed.

Founded in 2021, Isomorphic Labs was established as a standalone company to commercialize AlphaFold, the Google DeepMind-developed AI system that predicts the three-dimensional structures of proteins. Since protein structure is fundamental to drug development, the technology can help researchers identify promising drug candidates more quickly than traditional laboratory methods.

ALSO READ: Legal Tech Startup BrentWorks Launches AI Citation Verification Tool

Demis Hassabis leads Isomorphic Labs while also serving as chief executive of Google DeepMind. The company has recruited extensively from DeepMind since its launch.

The fundraising comes as investor interest in AI-driven drug discovery continues to grow. Earlier this year, OpenAI, another Thrive Capital portfolio company, introduced a new model designed to support drug discovery workflows.

Isomorphic Labs has signed partnerships with Johnson & Johnson, Eli Lilly and Company, and Novartis, although financial terms of the agreements have not been publicly disclosed.

The planned funding round would mark a significant increase in external capital for Isomorphic Labs, which began raising outside investment in 2024. It also reflects Alphabet’s broader strategy of turning research projects into standalone businesses, as seen with Waymo and its investments in Anthropic and SpaceX.

Disclaimer: This news is based on publicly available information. NervNow has not independently verified any claims.

DISCOVER LATEST AI INDUSTRY UPDATES
ElevenLabs Crosses $500M ARR as BlackRock, NVIDIA Back Series D Extension
Why CoreWeave’s Best Quarter Ever Still Sent Its Stock Down
James Dyett Exits OpenAI, Joins Thrive Capital in Latest Executive Shakeup
Meesho Says Over 70% of Its Code Is Now AI-Generated